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fluticasone furoate/vilanterol (50/25 mg;
100/25 mg) on lung function in COPD”
[Respir Med, 107 (2013) 560e569]Edward M. Kerwin a,*, Catherine Scott-Wilson b, Lisa Sanford c,
Stephen Rennard d, Alvar Agusti e, Neil Barnes f, Courtney Crim baClinical Research Institute of Southern Oregon, 3860 Crater Lake Avenue, Medford, OR 97504, USA
bGlaxoSmithKline, Research Triangle Park, NC, USA
c Formerly GlaxoSmithKline, Stockley Park, London, UK
dUniversity of Nebraska, Omaha, NE, USA
eThorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona and FISIB, CIBERES, Mallorca, Spain
fRespiratory Medicine, Barts and The London NHS Trust, London, UKThe authors regret that there were errors in the ‘Efficacy: co-primary’, Table 2 and Table 3 sections of the above paper.
The errors are shown below.The authors apologise for any inconvenience caused.
[Location]: Current incorrect text printed in article Text should correctly read
[p.563. Efficacy: co-primary section]: Furthermore,
compared with FF 100 mg alone, FF/VI 100/25 mg
significantly improved the adjusted mean wm FEV1
at day 168 by 120 ml (95% CI: 7, 170; p < 0.001) (Table 2).
Furthermore, compared with FF 100 mg alone,
FF/VI 100/25 mg significantly improved the
adjusted mean wm FEV1 at day 168 by 120 ml
(95% CI: 70, 170; p < 0.001) (Table 2).
[p.566, Table 2. footnote]: CRQ-SAS dyspnoea domain is
scaled from 0 to 7, with 0 indicating no impairment
CRQ-SAS dyspnoea domain is scaled from 1 to 7,
with 1 indicating no impairment
[p.567, Table 3. n-value for ocular effects in FF 100 group]: 1 (<1) 2 (<1)
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